Castle Biosciences, Inc., has announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a price to the public of US$37.00 per share. The gross proceeds to Castle Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be US$74.0 million. In addition, Castle Biosciences has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the offering price, less the underwriting discounts and commissions.

Latham & Watkins LLP represents Castle Biosciences, Inc. in the public offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Anthony Gostanian and Kiara Vaughn.